M&A Activity in the Biotech Industry at a Four-Year High as Large Pharmaceuticals Look to Replace Lose Revenues
August 17 2012 - 8:20AM
Marketwired
Biotechnology stocks continue to be some of the strongest
performers in the markets as favorable legislation, such as the
FAST and TREAT acts, have helped boost investor optimism within the
industry. The iShares Nasdaq Biotechnology Index Fund is up over 28
percent in 2012 -- handedly outperforming the Dow Jones industrial
average year-to-date. Five Star Equities examines the outlook for
companies in the Biotech Industry and provides equity research on
AEterna Zentaris Inc. (NASDAQ: AEZS) and Cytokinetics, Inc.
(NASDAQ: CYTK).
Access to the full company reports can be found at:
www.FiveStarEquities.com/AEZS
www.FiveStarEquities.com/CYTK
The FAST and TREAT acts introduced in 2012 have helped
accelerate the development, review and approval process of
medicines/personalized therapies for patients suffering from
serious and life-threatening diseases. According to recent data
from Thomas Reuters, biotech mergers & acquisitions activity is
currently at a four-year high as large pharmaceuticals are facing
major patent cliffs. So far in 2012 the volume of biotech M&A
has exceeded $25 billion, compared to roughly 10 billion in the
same period of 2011.
"Their patents have expired, and as a result they have holes in
their revenue line they are trying to fill," said Scott Lindsay,
global head of mergers and acquisitions at Credit Suisse. "The
other part is just shoring up the pipeline they have. So even if
they don't have a major patent problem, they're all looking for
growth."
Five Star Equities releases regular market updates on the
Biotech Industry so investors can stay ahead of the crowd and make
the best investment decisions to maximize their returns. Take a few
minutes to register with us free at www.FiveStarEquities.com and
get exclusive access to our numerous stock reports and industry
newsletters.
AEterna Zentaris is an oncology and endocrinology drug
development company currently investigating treatments for various
unmet medical needs. The Company's pipeline encompasses compounds
at all stages of development, from drug discovery through to
marketed products. For the second quarter 2012 the company reported
a net income of $4.5 million, compared to a net loss of 10.6
million in the year prior quarter.
Cytokinetics is a clinical-stage biopharmaceutical company
focused on the discovery and development of novel small molecule
therapeutics that modulate muscle function for the potential
treatment of serious diseases and medical conditions. Cytokinetics'
lead drug candidate from its cardiac muscle contractility program,
omecamtiv mecarbill, is in Phase II clinical development for the
potential treatment of heart failure.
Five Star Equities provides Market Research focused on equities
that offer growth opportunities, value, and strong potential
return. We strive to provide the most up-to-date market activities.
We constantly create research reports and newsletters for our
members. Five Star Equities has not been compensated by any of the
above-mentioned companies. We act as an independent research portal
and are aware that all investment entails inherent risks. Please
view the full disclaimer at:
www.FiveStarEquities.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: Five Star Equities Email Contact
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jul 2023 to Jul 2024